Elixir Medical Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Novolimus Eluting Coronary Bioadaptor System

Recruiting

Conditions: Coronary Artery Disease

Interventions: Device: DynamX Novolimus-eluting Coronary Bioadaptor System

First Posted Date: 2023-10-10

Last Posted Date: 2024-04-23

Lead Sponsor: Elixir Medical Corporation

Target Recruit Count: 5000

Registration Number: NCT06074549

Locations: 🇸🇦
King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia

A Clinical Trial to Assess the Elixir Medical LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter

Not Applicable

Completed

Conditions: Coronary Artery Disease

Interventions: Device: LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter (LithiX Coronary HCIVLC; LithiX)

First Posted Date: 2023-04-25

Last Posted Date: 2025-03-06

Lead Sponsor: Elixir Medical Corporation

Target Recruit Count: 60

Registration Number: NCT05828173

Locations: 🇧🇪
ZNA Middelheim, Antwerp, Belgium
🇧🇪
Ziekenhuis Oost-Limburg, Campus Sint Jan, Genk, Belgium
🇧🇪
Universitaire Ziekenhuizen Leuven, Leuven, Belgium

and more 4 locations

DYNAMX Bioadaptor ImplanTation for the trEatment of Complex Coronary Lesions

Not Applicable

Active, not recruiting

Conditions: Multi Vessel Coronary Artery Disease
Coronary Artery Disease
Long Lesions Coronary Artery Disease
Chronic Total Occlusion of Coronary Artery
Bifurcation of Coronary Artery

Interventions: Device: DynamX Drug-Eluting Coronary Bioadaptor System

First Posted Date: 2022-07-19

Last Posted Date: 2023-09-21

Lead Sponsor: Elixir Medical Corporation

Target Recruit Count: 55

Registration Number: NCT05464147

Locations: 🇮🇹
Humanitas Research Hospital, Rozzano, Italy

The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions

Phase 2

Active, not recruiting

Conditions: Coronary Artery Disease

Interventions: Combination Product: Percutaneous Coronary Intervention with drug eluting stents

First Posted Date: 2021-09-05

Last Posted Date: 2024-08-27

Lead Sponsor: Elixir Medical Corporation

Target Recruit Count: 200

Registration Number: NCT05033964

Locations: 🇳🇱
Catharina Hospital, Eindhoven, Netherlands
🇧🇪
AZ Sint Jan Brugge Oostende AV, Brugge, Belgium
🇧🇪
Ziekenhuis Oost-Limburg, Campus Sint Jan, Genk, Belgium

and more 11 locations

Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)

Not Applicable

Active, not recruiting

Conditions: Ischemic Heart Disease
Coronary Artery Disease

Interventions: Device: DynamX Bioadaptor
Device: Resolute Onyx

First Posted Date: 2020-09-24

Last Posted Date: 2024-10-16

Lead Sponsor: Elixir Medical Corporation

Target Recruit Count: 2400

Registration Number: NCT04562805

Locations: 🇸🇪
Centralsjukhuset Karlstad, Karlstad, Sweden
🇸🇪
Skånes Universitetssjukhus i Lund, Lund, Sweden
🇸🇪
Akademiska Sjukhuset, Uppsala, Sweden

and more 16 locations

DynamX Bioadaptor Hong Kong Registry

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Combination Product: DynamX Novolimus Eluting Coronary Bioadaptor System

First Posted Date: 2020-07-23

Last Posted Date: 2024-10-17

Lead Sponsor: Elixir Medical Corporation

Target Recruit Count: 50

Registration Number: NCT04483791

Locations: 🇨🇳
Kwong Wah Hospital, Hong Kong, Kowloon, China
🇨🇳
Queen Elizabeth Hospital, Hong Kong, Kowloon, China
🇨🇳
Chinese University of Hong Kong / Prince of Wales Hospital, Hong Kong, Sha Tin, China

and more 1 locations

DESyne X2 Post Market Follow-up Study

Not Applicable

Terminated

Conditions: Coronary Artery Disease

Interventions: Device: Percutaneous Coronary Intervention

First Posted Date: 2020-05-05

Last Posted Date: 2023-10-25

Lead Sponsor: Elixir Medical Corporation

Target Recruit Count: 49

Registration Number: NCT04375085

Locations: 🇨🇳
Kwong Wah Hospital, Hong Kong, Kowloon, China
🇨🇳
Queen Elizabeth Hospital, Hong Kong, Kowloon, China
🇨🇳
Tseung Kwan O Hospital, Hong Kong, China

The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries

Not Applicable

Active, not recruiting

Conditions: Coronary Disease
Coronary Artery Disease
Coronary Artery Stenosis
Coronary Stenosis

Interventions: Device: Percutaneous Coronary Intervention

First Posted Date: 2019-12-10

Last Posted Date: 2025-03-24

Lead Sponsor: Elixir Medical Corporation

Target Recruit Count: 445

Registration Number: NCT04192747

Locations: 🇧🇪
AZ Middelheim Hospital, Antwerp, Belgium
🇩🇪
Elisabeth Krankenhaus Essen, Essen, Germany
🇩🇪
Kerkhoff Klinik GmbH, Bad Nauheim, Germany

and more 33 locations

Elixir Medical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - Cx Registry

Not Applicable

Completed

Conditions: Coronary Artery Disease

Interventions: Device: DESolve Cx drug eluting coronary scaffold system

First Posted Date: 2019-07-26

Last Posted Date: 2021-07-14

Lead Sponsor: Elixir Medical Corporation

Target Recruit Count: 50

Registration Number: NCT04034121

Locations: 🇧🇪
St. - Jan Ziekenhuis Z.O.L., Genk, Belgium
🇧🇷
Instituto Dante Pazzanese, Sao Paulo, Brazil
🇧🇪
AZ Middelheim Hospital, Antwerp, Belgium

DynamX Sirolimus Study Sirolimus Eluting Coronary Bioadaptor System

Not Applicable

Completed

Conditions: Coronary Artery Disease

Interventions: Device: DynamX Sirolimus-eluting Coronary Bioadaptor System

First Posted Date: 2018-08-16

Last Posted Date: 2021-04-26

Lead Sponsor: Elixir Medical Corporation

Target Recruit Count: 44

Registration Number: NCT03634020

Locations: 🇳🇿
Dunedin Hospital, Dunedin, New Zealand
🇳🇿
Middlemore Hospital, Auckland, New Zealand
🇳🇿
North Shore Hospital, Auckland, New Zealand

and more 4 locations

Home Terms & Conditions Privacy Policy